公开(公告)号：US20200246475A1

公开(公告)日：2020-08-06

申请号：US16852697

申请日：2020-04-20

Applicant: Pfizer Inc.

Inventor： Jianxin Gu ,  Rajesh Kumar Kainthan ,  Jin-Hwan Kim ,  Avvari Krishna Prasad ,  Yu-Ying Yang

IPC: A61K47/64 ,  A61K39/09

Abstract: The present invention relates generally to glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a spacer containing ((2-oxoethyl)thio)). In an aspect the invention provides oxo-eT linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a ((2-oxoethyl)thio) spacer having the formula (I): wherein: A is a group (C═X)m wherein X is S or O and m is 0 or 1; B is a bond, O, or CH2; and when m is 0, B can also be (C═O); R is a C2-C16 alkylene, C2-C16 heteroakylene, NH—C(═O)—C2-C16 alkylene, or NH—C(═O)—C2-C16 heteroakylene, wherein said alkylene and heteroalkylene are optionally substituted by 1, 2 or 3 groups independently selected from COOR′ where R′ is selected from H, methyl, ethyl or propyl. The invention further relates to immunogenic compositions comprising such glycoconjugates, and to methods for the preparation and use of such glycoconjugates and immunogenic compositions.

公开(公告)号：US20190142922A1

公开(公告)日：2019-05-16

申请号：US16245378

申请日：2019-01-11

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Amardeep Singh Bhupender Bhalla ,  Robert G.K. Donald ,  Jianxin Gu ,  Kathrin Ute Jansen ,  Rajesh Kumar Kainthan ,  Lakshmi Khandke ,  Jin-Hwan Kim ,  Paul Liberator ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Ingrid Lea Scully ,  Suddham Singh ,  Cindy Xudong Yang

IPC: A61K39/09 ,  A61K39/40 ,  A61K47/26 ,  C07K16/12 ,  C07K16/44 ,  A61K47/10 ,  A61K39/39

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

公开(公告)号：US09492559B2

公开(公告)日：2016-11-15

申请号：US14597488

申请日：2015-01-15

Applicant: Pfizer Inc.

Inventor： Emilio Anthony Emini ,  Wendy Jo Watson ,  Avvari Krishna Prasad ,  Mingming Han ,  Jin-Hwan Kim ,  Jianxin Gu ,  Yu-ying Yang ,  Rajesh Kumar Kainthan ,  David Cooper ,  Michael William Pride ,  Kathrin Ute Jansen

IPC: A61K39/00 ,  A61K39/02 ,  A61K39/09 ,  A61K39/385 ,  A61K47/48

CPC classification number: A61K47/4833 ,  A61K39/092 ,  A61K47/646 ,  A61K2039/6037 ,  A61K2039/70 ,  Y02A50/466

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

Abstract translation: 本发明涉及包含结合性肺炎链球菌荚膜糖抗原（糖缀合物）的新的免疫原性组合物及其应用。 本发明的免疫原性组合物通常将包含至少一种来自PREVNAR，SYNFLORIX和/或PREVNAR 13中没有发现的肺炎链球菌血清型的糖缀合物。 本发明还涉及使用所述新型免疫原性组合物对人受试者，特别是婴儿和老年人免疫肺炎球菌感染。

公开(公告)号：US20160324950A1

公开(公告)日：2016-11-10

申请号：US15144884

申请日：2016-05-03

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Amardeep Singh Bhupender Bhalla ,  Robert G.K. Donald ,  Jianxin Gu ,  Kathrin Ute Jansen ,  Rajesh Kumar Kainthan ,  Lakshmi Khandke ,  Jin-Hwan Kim ,  Paul Liberator ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Ingrid Lea Scully ,  Suddham Singh ,  Cindy Xudong Yang

IPC: A61K39/09 ,  A61K39/40 ,  A61K47/10 ,  A61K39/39 ,  A61K47/26

CPC classification number: A61K39/092 ,  A61K39/39 ,  A61K39/40 ,  A61K47/10 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/55 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/55577 ,  A61K2039/6037 ,  A61K2039/70 ,  C07K16/1275 ,  C07K16/44 ,  Y02A50/484

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Abstract translation: 本发明涉及免疫原性多糖 - 蛋白质缀合物，其包含通常称为B族链球菌（GBS）的无乳链球菌的荚膜多糖（CP）和载体蛋白，其中CP选自血清型Ia，Ib ，II，III，IV，V，VI，VII，VIII和IX，并且其中CP具有大于约60％的唾液酸水平。 本发明还涉及制备缀合物和包含缀合物的免疫原性组合物的方法。 本发明还涉及包含多糖 - 蛋白质缀合物的免疫原性组合物，其中缀合物包含来自GBS血清型IV的CP和至少一种另外的血清型。 本发明还涉及使用本文公开的组合物在受试者中诱导免疫应答的方法，所述方法用于针对GBS和/或用于减少或预防受试者的侵袭性GBS疾病。 所得抗体可用于通过被动免疫治疗来治疗或预防GBS感染。